Abstract 1385P
Background
Despite improvements in therapy, lung adenocarcinoma (LUAD) mortality remains high, with fewer than 20% of patients surviving after 5 years. Therefore, overcoming resistance to the already existing therapies and identifying new strategies remains a high priority. Approximately 20% of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant LUAD carry loss-of-function (LOF) KEAP1 mutations, which confer the worst prognosis of all LUAD subtypes as patients do not respond to standard of care, radiation, immunotherapy, chemotherapy or covalent KRASG12C inhibitors.
Methods
Here, we used two (2D) and three-dimensions (3D) in vitro cultures and in vivo pre-clinical models to uncover resistance mechanisms and also vulnerabilities of KEAP1-mutant LUAD.
Results
We found that, although Keap1 loss did not lead to growth differences in 2D cultures, in 3D its loss led to increased spheroids’ size (p<0.001) and higher EdU staining. Importantly, similar patterns were seen with the pharmacological inhibition of Keap1 by KI696 and rescued by the knockout of NRF2. In addition, we observed an increased expression of NRF2 targets, NQO1 (p<0.01) and HO1 (p<0.001), in Keap1-knockout spheroids compared to those cultured in two-dimensions, suggesting a greater requirement of NRF2 pathway in the 3D system. We also explored how Keap1-mutated tumors respond to KRAS inhibitors (KrasG12Di). Keap1-low/NRF2-high tumors were significantly less sensitive to the newly developed KrasG12D inhibitor, MRTX1133 (Mirati Therapeutics), measured by both tumor size (p<0.05) and tumor weight at end point (p=0.01). RNAseq of lung spheroids treated with MRTX1133 are being performed to bring to light how the loss of Keap1 is able to support survival upon the treatment with KrasG12D inhibitors.
Conclusions
Taken together these findings will contribute to the understanding of resistance mechanisms and will give us insights of therapeutic strategies to determine the best-individualized treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fernando Simabuco and Thales Papagiannakopoulos.
Funding
The São Paulo Research Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1393TiP - A phase II/III study to evaluate the optimal dose, safety, and efficacy of livmoniplimab (Livmo) in combination with budigalimab (Budi) plus chemotherapy (CT) vs pembrolizumab (Pembro) plus CT in untreated metastatic non-small cell lung cancer (mNSCLC)
Presenter: Nicolas Girard
Session: Poster session 06
1394TiP - KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation
Presenter: Marina Garassino
Session: Poster session 06
1395TiP - A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02)
Presenter: Antonio Passaro
Session: Poster session 06
1397TiP - Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy
Presenter: Stephen Liu
Session: Poster session 06
Resources:
Abstract
1398TiP - Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
Presenter: Solange Peters
Session: Poster session 06
1399TiP - Phase III, double-blind study of cannabis sativa extract in pain management and quality of life in patients with metastatic lung cancer: Protocol of a study (IPElife trial)
Presenter: Danielli Matias
Session: Poster session 06
1728P - Results of TNT: A phase II study using talimogene laherparepvec, nivolumab and trabectedin for advanced leiomyosarcoma and liposarcoma [NCT# 03886311]
Presenter: Sant Chawla
Session: Poster session 06
1729P - Update on SAINT: A phase II study using trabectedin (T) in combination with ipilimumab (I) and nivolumab (N) in previously treated soft tissue sarcoma
Presenter: Anmol Dia Agarwal
Session: Poster session 06
1730P - Preliminary results of phase II study on preoperative intensity-modulated radiotherapy with concurrent PARP inhibitor for patients with non-metastatic inoperable or borderline operable extremity and trunk soft tissue sarcoma
Presenter: NingNing Lu
Session: Poster session 06
Resources:
Abstract